SCHEMBL13628896

SCHEMBL13628896

CCCCOc1ccc(CCC(N)(CO)CO)cc1

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 12/20 0.69
S1PR3 Q99500 8/20 0.69
TNNC1 P63316 6/20 0.69
S1PR4 O95977 5/20 0.69
S1PR5 Q9H228 4/20 0.69
SGPL1 O95470 1/20 0.69
GPR183 P32249 1/20 0.69
CERS2 Q96G23 1/20 0.69
SPHK2 Q9NRA0 2/20 0.59
SPHK1 Q9NYA1 1/20 0.59
S1PR2 O95136 1/20 0.57
ALOX15 P16050 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3393863 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL3391015 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL2010273 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL3389424 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL3393534 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
Hydrochloric Acid SCHEMBL8498173 0.96 S1PR1 (0.71) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL3394918 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL3393258 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
SCHEMBL3393720 0.96 S1PR1 (0.73) S1PR1S1PR3TNNC1S1PR4S1PR5
Hydrochloric Acid SCHEMBL8496359 0.94 S1PR1 (0.74) S1PR1S1PR3TNNC1S1PR4S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612238-B2 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases NOVARTIS AG (CH) 2009-11-03 US disclosed